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Abstract
Background—Antenatal corticosteroid (ANCS) treatment hastens fetal lung maturity and 
improves survival of premature infants, but the long-term effects of ANCS are not well-described. 
Animal models suggest ANCS increases the risk of cardiovascular disease through programmed 
changes in the renin-angiotensin (Ang)-aldosterone system (RAAS). We hypothesized that ANCS 
exposure alters the RAAS in adolescents born prematurely.
Methods—A cohort of 173 adolescents born prematurely was evaluated, of whom 92 were 
exposed to ANCS. We measured plasma and urine Ang II and Ang-(1–7) and calculated Ang II/
Ang-(1–7) ratios. We used general linear regression models to estimate the difference in the RAAS 
between the ANCS-exposed and unexposed groups, adjusting for confounding variables.
Results—In unadjusted analyses, and after adjustment for sex, race, and maternal hypertension, 
ANCS exposure was associated with increased urinary Ang II/Ang-(1–7) [estimate 0.27 (95% CI 
*Corresponding Author: Andrew M. South, MD, MS, Section of Nephrology, Department of Pediatrics, Wake Forest School of 
Medicine, One Medical Center Boulevard, Winston Salem, NC 27157, Phone (336) 716-9640, Fax (336) 716-9229, 
asouth@wakehealth.edu. 
Potential Conflicts of Interest: The authors have no conflicts of interest relevant to this article to disclose.
Category of Study: Translational research
HHS Public Access
Author manuscript
Pediatr Res. Author manuscript; available in PMC 2017 October 18.
Published in final edited form as:
Pediatr Res. 2017 January ; 81(1-1): 88–93. doi:10.1038/pr.2016.179.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
0.03, 0.5), p = 0.03], increased plasma Ang-(1–7) [0.66 (0.26, 1.07), p = 0.002], and decreased 
plasma Ang II/Ang-(1–7) [−0.48 (−0.91, −0.06), p = 0.03].
Conclusions—These alterations indicate an imbalance in the urinary RAAS, promoting the 
actions of Ang II at the expense of Ang-(1–7), which over time may increase the risk of renal 
inflammation and fibrosis and ultimately hypertension and renal disease.
Introduction
Antenatal corticosteroids (ANCS), given to pregnant women expected to deliver prematurely 
to accelerate fetal lung maturity, increases survival and improves outcomes in the offspring, 
but the long-term effects of ANCS are not well-characterized (1–3). Data from preclinical 
models that simulate human exposure suggest that ANCS may increase the risk for 
hypertension (HTN) and cardiovascular disease (4, 5). The increased risk may be mediated 
in part by chronic dysregulation of the renin-angiotensin (Ang)-aldosterone system (RAAS), 
leading to increased renal and cardiovascular disease in adulthood (6, 7). Human studies 
offer conflicting conclusions regarding relationships between ANCS exposure and 
cardiovascular outcomes in adolescents and young adults and have not evaluated the effect 
of ANCS exposure on the RAAS (8–12).
The RAAS includes the Ang-converting enzyme (ACE)/Ang II pathway and the ACE2/Ang-
(1–7) pathway, is important in renal and cardiovascular development, and is subject to 
developmental changes early in life (13, 14). Ang II is a vasoconstrictor, enhances sodium 
retention directly and through stimulation of aldosterone, and promotes inflammation and 
fibrosis, while Ang-(1–7) has variable effects on sodium transport and glomerular filtration 
and has anti-inflammatory and anti-fibrotic effects in numerous organ systems, including the 
kidney (6, 15–19). An altered RAAS is associated with adverse health outcomes, including 
HTN and chronic kidney disease (20). RAAS components measured in the urine are markers 
of the intrarenal RAAS (21–23). We measured RAAS components in adolescents born 
prematurely to evaluate the hypothesis that ANCS exposure is associated with long-term 
alteration of the balance between Ang II and Ang-(1–7) in plasma and urine.
Results
Study Population (Table 1)
Reflective of the larger ANCS study’s design, approximately half the study sample was born 
to mothers who received ANCS (53%). The majority of subjects were female (55%), 43% 
were black, and 35% were overweight/obese at 14 years of age. Maternal HTN complicated 
36% of pregnancies. Blacks were less likely to receive ANCS. The ANCS group had a 
higher rate of maternal HTN and was taller.
ANCS Exposure and Urinary RAAS
There were no differences in Ang II, Ang II/creatinine, Ang-(1–7), or Ang-(1–7)/creatinine 
(Table 1). Ang II/Ang-(1–7) was higher in the ANCS group and this difference persisted 
when adjusting for race, sex, and maternal HTN [estimate 0.27 (95% CI 0.03, 0.5), p = 0.03] 
(Table 2).
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ANCS Exposure and Plasma RAAS
There were no differences in plasma renin activity (PRA), aldosterone, aldosterone-to-renin 
ratio (ARR), or Ang II (Table 1). The ANCS group had higher plasma Ang-(1–7) and lower 
Ang II/Ang-(1–7), and these differences persisted when adjusted for race, sex, and maternal 
HTN [Ang-(1–7): 0.66 (0.26, 1.07), p = 0.002; Ang II/Ang-(1–7): −0.48 (−0.91, −0.06), p = 
0.03] (Table 2, Figure 1). The associations of ANCS with higher plasma Ang-(1–7) and 
lower Ang II/Ang-(1–7) were stronger among black study participants (Figure 2) [Ang-(1–
7): 1.13 (0.61, 1.66), p <0.001; Ang II/Ang-(1–7): −0.91 (−1.48, −0.33), p = 0.003].
Although log-transformed waist-to-height ratio was associated with both plasma Ang-(1–7) 
and Ang II/Ang-(1–7) [−1.44 (−2.65, −0.23), p = 0.02; 2.26 (1.04, 3.47), p <0.001], adding 
waist-to-height ratio to the regression models did not substantially alter the association 
between ANCS and plasma RAAS.
Discussion
Among adolescents born prematurely, ANCS exposure was associated with increased 
urinary Ang II/Ang-(1–7), increased plasma Ang-(1–7), and decreased plasma Ang II/Ang-
(1–7). The increased urinary Ang II/Ang-(1–7) among preterm adolescents exposed to 
ANCS may be due to a higher renal (urinary) Ang II. This shift in the kidney, towards Ang 
II and away from Ang-(1–7), is consistent with the finding that offspring of pregnant ewes 
exposed to clinically relevant doses of ANCS (betamethasone given at 0.6 gestation: the 
equivalent of about 24 weeks gestation in humans) develop alterations in the renal RAAS, 
decreased renal function, and elevated blood pressure as adults. RAAS alterations include 
attenuated responses to Ang-(1–7), enhanced responses to Ang II, increased expression of 
the Ang II type 1 receptor, increased serum ACE activity, decreased serum ACE2 activity, 
and decreased proximal tubular ACE2 activity and expression. Together these alterations 
indicate an imbalance in the RAAS which promotes the actions of Ang II at the expense of 
Ang-(1–7) (6, 7, 24, 25).
Over time, elevated renal Ang II levels could increase the risk for renal inflammation and 
fibrosis and may lead to HTN and renal disease (26). This mechanism could accentuate 
other perinatal renal insults such as ischemia and nephrotoxic exposure (21, 27). In contrast 
to RAAS alterations in urine, plasma levels of Ang-(1–7) were higher among ANCS-
exposed adolescents, which might serve to attenuate the physiologic effects of an elevated 
Ang II to Ang-(1–7) ratio in the kidney. A potential explanation for this finding is that it may 
reflect a compensatory upregulation to counteract further inflammation and fibrosis by Ang 
II as ACE2 expression and elevated Ang-(1–7) levels are evident in several pathologic states 
(28, 29). ANCS exposure could also directly lead to increased systemic or vascular ACE2/
Ang-(1–7) pathway activity.
Consistent with data showing obesity is associated with an upregulated ACE/Ang II pathway 
(30), we found that waist-to-height ratio, a measure of central adiposity, was associated with 
decreased plasma Ang-(1–7) and increased plasma Ang II/Ang-(1–7). Obesity-driven RAAS 
dysregulation is associated with inflammation, insulin resistance, and metabolic disease 
(31). Racial differences in PRA and aldosterone are well-documented. Our finding that 
South et al. Page 3
Pediatr Res. Author manuscript; available in PMC 2017 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
associations between ANCS and the RAAS were stronger among black study participants 
suggests the possibility that long-term effects of ANCS might differ for blacks and non-
blacks.
Our study is limited by the non-randomized allocation of the exposure (ANCS), leaving 
open the possibility of confounding due to factors we did not measure. We could not fully 
account for all the potential factors that influence the RAAS, such as genetic influences and 
dietary variability. Further, we lack measurements of RAAS enzymatic activity, specifically 
ACE and ACE2, which could better characterize the profiles of the ACE/Ang II and ACE2/
Ang-(1–7) pathways in this cohort.
In conclusion, in a cohort of adolescents born prematurely, ANCS exposure was associated 
with alterations in the RAAS, specifically increased urinary Ang II/Ang-(1–7), increased 
plasma Ang-(1–7), and decreased plasma Ang II/Ang-(1–7). An altered systemic and 
intrarenal RAAS may modify an individual’s cardiovascular risk profile and negatively 
impact kidney function later in life.
Methods
Study Participants
Study participants were recruited from among living members of a premature birth cohort of 
193 patients born between January 1, 1992 and June 30, 1996 at a regional perinatal center 
(Forsyth Medical Center in Winston Salem, NC). This cohort included i) children with 
whom we had contact through at least one year of age, ii) were not wards of the state, and 
iii) were successfully contacted at 14 years of age. Sixty-two percent of those contacted 
were enrolled (n = 193). Of the 193 cohort subjects, seven were excluded from the analysis 
(two were twins, three had congenital anomalies, and two had maternal oral steroid use). 
The members of the cohort were evaluated at 14 years of age as part of a larger study of 
ANCS exposure and cardiovascular and metabolic outcomes among preterm adolescents 
(Figure 3). We report the measurements made at the third study visit, at which 173 subjects 
were evaluated (92 of 94 in the ANCS group, 81 of 92 in the unexposed group). All the 
subjects provided urine specimens and 120 provided blood specimens. More detailed 
information on materials and methods, including specific inclusion and exclusion criteria, 
have been published previously (32). The Wake Forest School of Medicine and Forsyth 
Medical Center Institutional Review Boards approved the study. We obtained informed 
consent from parents or legal guardians and assent from participants.
Data Collection
Perinatal characteristics were recorded from medical records and research databases. We 
recorded the presence of maternal hypertension during pregnancy (maternal HTN) and 
ANCS exposure, defined as maternal treatment with betamethasone and/or dexamethasone 
(one subject’s mother received dexamethasone only and one subject’s mother received both 
betamethasone and dexamethasone). Birth characteristics were noted, including i) sex, ii) 
GA, and iii) birth weight. Birth weight z score was determined (33). We categorized subjects 
as born SGA if their birth weight percentile was less than or equal to the 10% (34). 
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Demographic information was recorded at 14 years of age, including parental-reported race 
(black vs non-black), and height, weight, and waist circumference were measured. We 
calculated BMI (kg/m2) and waist-to-height ratio, and defined overweight/obese as BMI 
≥85% for age and sex (35). Sexual maturity was rated (1 to 5) using a self-reported 
questionnaire completed in private and was summarized as the average of both determinants 
of secondary sexual characteristics (external genitalia development and pubic hair in males; 
breast development and pubic hair in females) (36). Resting blood pressure was measured 
with a mercury manometer after the subject was seated quietly for at least five minutes, and 
the average of three measurements was recorded according to established guidelines (37). 
Blood pressure z scores were calculated (38).
Laboratory Measurements
Blood was collected from participants in the seated position to measure PRA, aldosterone, 
Ang-(1–7), and Ang II. A spot urine sample was provided to measure Ang-(1–7), Ang II, 
and creatinine. We calculated ARR, the Ang II/Ang-(1–7) ratio in the plasma and urine, and 
the urinary Ang-(1–7) and Ang II concentrations corrected for creatinine. Specific laboratory 
methods have been published previously (39).
Statistical Analyses
Distributions of continuous variables were described with the mean and SD or the median 
and IQR. We used natural logarithmic transformation to improve the distributional 
characteristics of the continuous variables when appropriate. Values below the minimum 
detectable thresholds were assigned one-half those threshold values (39). For between-group 
comparisons of continuous variables, we used the t-test and Wilcoxon Rank-Sum test; for 
comparisons of categorical variables we used the Chi-square and Fisher’s Exact tests. 
Correlations were assessed with Pearson or Spearman correlation coefficients.
We used general linear regression models to evaluate the relationship of ANCS exposure and 
RAAS outcomes. We evaluated effect modification using product terms (ANCS × modifier). 
To identify variables that might confound the ANCS – RAAS relationships we evaluated 
bivariate relationships between each potential confounder and ANCS and each potential 
confounder and RAAS outcome. Potential confounders were included in the multivariate 
models if either of the following were found: i) an association with both the RAAS measure 
and ANCS at p <0.2, or ii) a >10% change in the regression coefficient for ANCS estimated 
with general linear models. In addition, sex, race, and maternal HTN were identified a priori 
as potential confounders and effect modifiers, based on the results of previous studies (39, 
40). The criterion for inclusion in the final multivariate model was p <0.05. For comparisons 
of the ANCS-exposed and unexposed groups, a two-sided alpha of 0.05 was considered 
statistically significant. We used Enterprise Guide software, Version 7.11 of the SAS System 
for Windows (SAS Institute Inc., Cary, NC) for all analyses.
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Figure 1. 
Relationship between ANCS and RAAS
Gray arrows indicate direction of association with the RAAS: dark gray indicates 
upregulation of Ang II and light gray indicates upregulation of Ang-(1–7).
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Figure 2. 
ANCS and RAAS Stratified by Race
2a: Plasma Ang II/Ang-(1–7)
2b: Plasma Ang-(1–7)
*p = 0.002, **p <0.001. ANCS = dark gray; No ANCS = light gray. Bar denotes median, 
circle denotes mean, box indicates IQR, and whiskers include ≤1.5x IQR. Between-group 
comparisons by Wilcoxon Rank-Sum test.
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Figure 3. 
Study Participant Flow Diagram
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Table 1
Clinical Characteristics and the Renin-Angiotensin-Aldosterone System Profile at 14 Years
All Subjects ANCS No ANCS
Clinical Characteristics N = 173 92 (53%) 81 (47%)
Male 78 (45%) 44 (48%) 34 (42%)
Black 74 (43%) 27 (29%)* 47 (58%)
Maternal Hypertension 63 (36%) 40 (43%)* 23 (28%)
GA (weeks) 27.8 (2.6) 27.7 (2.4) 27.9 (2.9)
Birth Weight (g) 1053 (265) 1033 (269) 1075 (261)
Birth Weight z Score −0.29 (0.84) −0.35 (0.74) −0.22 (0.93)
SGA 21 (12%) 9 (10%) 12 (15%)
Height (cm) 161.6 (9.3) 163.2 (8.9)* 159.8 (9.5)
Weight (kg) 56.0 [47.5, 69.5] 56.6 [48.7, 68.6] 56.0 [46.3, 71.8]
BMI (kg/m2) 21.1 [18.6, 26.5] 20.5 [18.4, 26.0] 22.5 [19.0, 26.6]
Overweight/Obese 60 (35%) 28 (30%) 32 (40%)
Waist-to-Height Ratio 0.46 [0.42, 0.53] 0.45 [0.42, 0.51] 0.48 [0.43, 0.54]
Sexual Maturity Ratinga 4.5 [4.0, 5.0] 4.5 [4.0, 5.0] 4.5 [4.0, 5.0]
Systolic Blood Pressure 106.3 (9.9) 107.2 (10.4) 105.2 (9.2)
Systolic Blood Pressure z Score −0.40 (0.89) −0.36 (0.98) −0.45 (0.79)
Diastolic Blood Pressure 61.3 (8.9) 61.6 (8.9) 60.9 (8.9)
Diastolic Blood Pressure z Score −0.28 (0.78) −0.26 (0.79) −0.29 (0.77)
Urinary RAAS Profile N = 173 n = 92 n = 81
Ang-(1–7) (pmol/L) 70.1 [48.6, 94.8] 70.9 [44.6, 94.4] 68.7 [49.0, 98.4]
Ang-(1–7)/Creatinine (pmol/g) 0.41 [0.31, 0.59] 0.39 [0.29, 0.61] 0.43 [0.33, 0.57]
Ang II (pmol/L) 9.3 [6.3, 15.3] 10.5 [6.5, 16.6] 8.7 [5.9, 13.8]
Ang II/Creatinine (pmol/g) 0.05 [0.04, 0.1] 0.06 [0.04, 0.11] 0.05 [0.03, 0.1]
Ang II/Ang-(1–7) 0.15 [0.1, 0.23] 0.17 [0.1, 0.27]* 0.14 [0.1, 0.19]
Plasma RAAS Profile N = 120 n = 70 n = 50
PRA (pmol Ang I/L/h) 2.4 [1.2, 3.2] 2.5 [1.4, 3.2] 1.9 [1.0, 3.0]
Aldosterone (pmol/L) 9.9 [5.3, 14.1] 9.9 [6.2, 13.3] 9.9 [4.3, 17.8]
ARR (pmol/L per pmol Ang I/L/h) 4.2 [3.0, 6.6] 4.1 [3.1, 6.2] 4.6 [2.5, 8.7]
Ang-(1–7) (pmol/L) 5.6 [2.9, 13.5] 9.0 [2.6, 14.7]* 2.7 [1.4, 7.0]
Ang II (pmol/L) 21.5 [16.7, 32.1] 22.3 [17.1, 33.3] 21.0 [15.6, 29.1]
Ang II/Ang-(1–7) 3.7 [1.9, 6.8] 3.0 [1.6, 7.8]* 6.3 [3.5, 13.3]
N (%), mean (SD), median [IQR].
a
n = 154.
*
Denotes significant difference between groups with p <0.05 by chi-square test, t-test, or Wilcoxon Rank-Sum test.
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